The stock is a binary event driven by mid-2026 SIGNAL-AA data. The extended cash runway into 1H 2028 removes near-term financing risk, but the $75M ATM filed 11 days ago adds overhang. Monitor for any early data disclosures or analyst days ahead of the topline readout.
QTTB drugs
QTTB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $5.14entry
- T+1 · 7mo ago +6.42%α +5.04% · $5.47
- T+5 · 6mo ago +13.04%α +11.05% · $5.81
- T+20 · 6mo ago +145.91%α +140.96% · $12.64
- T+60 · 4mo ago +202.72%α +199.98% · $15.56
Price Chart
How similar events traded
Executive Summary
Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025, driven by lower R&D and G&A expenses. Cash runway extended into 1H 2028 following a $10.5M RDO and $14.2M ATM proceeds, with the key catalyst being mid-2026 topline data from the SIGNAL-AA Phase 2a trial for bempikibart. The sequential improvement in cash burn and extended runway are positive, but the stock remains a binary event driven by clinical data.
Key Financial Metrics
Key Facts
- Net loss narrowed to $7.6M ($0.54/share) in Q1 2026 from $11.0M ($0.90/share) in Q1 2025
- Cash and cash equivalents of $50.8M as of March 31, 2026, plus $14.2M in ATM proceeds received after quarter-end
- Cash runway extended into first half of 2028, from prior guidance of Q4 2027
- Bempikibart 36-week topline data from Part B of SIGNAL-AA Phase 2a trial on track for mid-2026
- First patient dosed in Part B open-label extension (OLE)
- R&D expenses fell to $3.2M from $7.1M YoY due to reduced headcount and lower clinical spend
- G&A expenses fell to $4.5M from $5.1M YoY due to lower legal and consulting costs
- ATM program raised $14.2M in gross proceeds after quarter-end; $75M ATM filed April 24, 2026
Financial Impact
Net loss improved by $3.4M YoY; cash position increased $2.5M sequentially; $24.7M in total capital raised (RDO + ATM) in Q1 2026
Risk Factors
- Phase 2a topline data may fail to meet efficacy endpoints, causing significant downside
- ATM overhang of up to $75M could pressure stock price regardless of clinical outcomes
- Pre-revenue biotech with no approved products; any clinical setback could threaten viability
- Small open-label trial (33 patients) limits statistical robustness of efficacy signals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-205006 |
| Document: qttb-20260505.htm | 0001193125-26-205006 |
| Document: 0001193125-26-205006-index-headers.html | 0001193125-26-205006 |
| Document: 0001193125-26-205006-index.html | 0001193125-26-205006 |
| Document: 0001193125-26-205006.txt | 0001193125-26-205006 |
| 8-K Data (Synthetic) | 0001193125-26-205006 |
Track record
23 reports on QTTB
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers